^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Source:
Title:

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

Excerpt:
...a 43 year-old white female who underwent a right salpingo-oophorectomy and endometrial ablation in the context of a ruptured ovarian cyst...Pathological evaluation of the liver mass was consistent with a moderately differentiated intrahepatic cholangiocarcinoma...Transcriptome analysis revealed the presence of an FGFR2-TACC3 fusion...She had been treated with pazopanib 800 mg orally daily for 4 months and demonstrated tumor shrinkage...She remains on therapy approximately 4 months since the initiation of ponatinib. As such, anti-tumor activity was obtained with two distinct FGFR inhibitors in the same patient.
DOI:
https://dx.doi.org/10.1371%2Fjournal.pgen.1004135